Bupropion SR Dosing for Smoking Cessation with Mood Stability
The described regimen of bupropion SR 150 mg once daily for 3 days, then increasing to 150 mg twice daily (300 mg/day total), with a quit date set 1-2 weeks after starting medication, is the correct evidence-based approach for smoking cessation. This dosing schedule is explicitly recommended in current clinical practice guidelines and FDA labeling 1.
Standard Dosing Protocol
The guideline-recommended approach is:
- Days 1-3: 150 mg orally once daily in the morning
- Day 4 onwards: 150 mg orally twice daily (300 mg/day total), if tolerated
- Quit date: Set for 1-2 weeks after initiating medication
- Duration: 7-12 weeks of treatment 1
This titration schedule minimizes seizure risk while allowing therapeutic drug levels to build before the quit date 1.
Key Implementation Points
Timing is critical: Starting bupropion 1-2 weeks before the quit date allows steady-state drug levels to be achieved, which improves cessation success rates 1, 2. The medication should be swallowed whole (not crushed or divided) and can be taken with or without food 3.
The twice-daily dosing matters: While 150 mg once daily can be used initially, the target therapeutic dose is 300 mg/day (150 mg BID), with a maximum of 300 mg per day 1. The evidence base for efficacy is strongest at this 300 mg/day dose 4.
Mood Stability Considerations
For patients with current or past depression, this same dosing regimen applies. The evidence shows that bupropion is effective for smoking cessation in patients with depression, and importantly, does not worsen depressive symptoms during quit attempts 5. In fact, adding psychosocial mood management to standard cessation interventions significantly improves outcomes in smokers with current depression (RR 1.47,95% CI 1.13-1.92) 5.
Monitor for neuropsychiatric effects: Although uncommon, providers should watch for development or worsening of depression, suicidal ideation, or behavioral changes, particularly in the first few weeks 1. However, recent large trials show neuropsychiatric adverse events with bupropion are not significantly increased compared to placebo 1.
Critical Safety Contraindications
Absolute contraindications include:
- Seizure disorder or conditions increasing seizure risk (stroke, brain metastases)
- Current use of MAO inhibitors
- Concurrent use with tamoxifen
- Closed-angle glaucoma 1
The seizure risk with bupropion is approximately 1 in 1000, similar to other antidepressants 2.
Behavioral Support Integration
Combine medication with behavioral counseling: The evidence for bupropion efficacy comes from trials that included behavioral support 2. Weekly follow-up sessions for at least 4 weeks after the quit date optimize outcomes 2.
Expected Outcomes
With this regimen, expect:
- End of treatment abstinence: 38-44% at 7 weeks 4
- Long-term abstinence: 23% at 1 year 4
- Minimal weight gain: Average 1.5-2.3 kg during treatment 4
Bupropion shows superior efficacy to placebo (RR 1.64,95% CI 1.52-1.77) but is less effective than varenicline (RR 0.71,95% CI 0.64-0.79) and equivalent to NRT (RR 0.99,95% CI 0.91-1.09) 6.
Common Pitfalls to Avoid
- Don't skip the titration period: Starting at 300 mg/day increases seizure risk
- Don't set the quit date too early: Allow the full 1-2 weeks for drug levels to build
- Don't forget to screen for seizure risk factors: This is the most serious contraindication
- Don't assume it won't work with other psychotropics: Bupropion has been safely combined with SSRIs for smoking cessation in depressed patients 7
The described plan is evidence-based and appropriate for smoking cessation with attention to mood stability.